Catalyst

Slingshot members are tracking this event:

OncoSec Medical (ONCS) Phase 2 Results Evaluating ImmunoPulse IL-12 and Merck's (MRK) Keytruda in Metastatic Melanoma

Source Link:
http://www.prnewswire.com/news-releases/oncosec-announces-positive-phase-ii-data-demonstrating-companys-immunopulse-il-12-in-combination-with-pembrolizumab-increased-response-rates-in-anti-pd-1-non-responder-melanoma-patients-300412643.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MRK
100%
ONCS
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 23, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Immunopulse Il-12, Keytruda, Metastatic Melanoma, Pd-1 Inhibition
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.